After RAS inhibitors: what comes next in pancreatic cancer?
RAS inhibitors have opened a new chapter in the treatment of pancreatic cancer, but some tumours develop resistance to these drugs. Here, we explor...
RAS inhibitors have opened a new chapter in the treatment of pancreatic cancer, but some tumours develop resistance to these drugs. Here, we explor...
In recent years, IDIBAPS has experienced significant growth in its activities, making it necessary to consolidate a robust, integrated and efficien...
A study led by the Clínic-IDIBAPS provides new clues about the genetic basis of psychotic disorders such as schizophrenia and bipolar disorder. Th...
The Clínic-IDIBAPS has led the development of EBI-BD, a new open-access, interactive web platform that synthesizes all the available scientific evi...
Thomas Walle, head of the IDIBAPS Computational cancer biomedicine group located in the Esther Koplowitz Center has received a Starting Grant from...
A study led by the IDIBAPS Molecular genetics of paediatric lymphomas research group located in the Esther Koplowitz Centerhas identified genetic,...
A study led by researchers from the Hospital Clínic-IDIBAPS, within the Clínic Barcelona Comprehensive Cancer Centre, has identified CD70 as a mark...
A study led by professionals from the Primary healthcare transversal research group at IDIBAPS and the Barcelona Esquerra Primary Healthcare Consor...
During three weeks, IDIBAPS has organized a science summer camp for children aged 5 to 12.
Part of the world is preparing for a total solar eclipse, one of the most anticipated astronomical phenomena. A moment when the Moon will completel...